Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Common Equity (2016 - 2026)

Champions Oncology (CSBR) has 15 years of Common Equity data on record, last reported at $4.2 million in Q4 2025.

  • For Q4 2025, Common Equity rose 512.33% year-over-year to $4.2 million; the TTM value through Oct 2025 reached $4.2 million, up 512.33%, while the annual FY2025 figure was $3.8 million, 298.21% up from the prior year.
  • Common Equity reached $4.2 million in Q4 2025 per CSBR's latest filing, up from $3.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $9.2 million in Q1 2022 and bottomed at -$2.1 million in Q1 2024.
  • Average Common Equity over 5 years is $4.7 million, with a median of $5.1 million recorded in 2023.
  • Peak YoY movement for Common Equity: crashed 141.05% in 2024, then skyrocketed 1165.66% in 2025.
  • A 5-year view of Common Equity shows it stood at $8.1 million in 2021, then grew by 13.64% to $9.2 million in 2022, then crashed by 98.99% to $93000.0 in 2023, then surged by 632.26% to $681000.0 in 2024, then surged by 512.33% to $4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $4.2 million in Q4 2025, $3.5 million in Q3 2025, and $3.8 million in Q2 2025.